Toceranib Phosphate: Veterinary Receptor Tyrosine Kinase Inhibitor
Toceranib phosphate is an oral multi-kinase inhibitor developed specifically for veterinary oncology. It inhibits several receptor tyrosine kinases including VEGFR2, PDGFRα/β, Kit, and Flt-3, blocking both tumor cell proliferation and angiogenesis. Toceranib is structurally related to sunitinib and was the first tyrosine kinase inhibitor approved for use in dogs.
Product Profile
| CAS Number | 874819-74-6 |
|---|---|
| Molecular Formula | C22H27FN4O2·H3PO4 |
| Appearance | Off-white to yellow powder |
| Therapeutic Category | Veterinary antineoplastic (tyrosine kinase inhibitor) |
| Storage | Room temperature |
Applications
Toceranib phosphate is approved for the treatment of canine mast cell tumors (Patnaik grade II or III) with or without regional lymph node involvement. It is administered orally to dogs at a recommended dose of 3.25 mg/kg every other day. Beyond mast cell tumors, veterinary oncologists use toceranib off-label for other canine solid tumors including anal sac adenocarcinoma, thyroid carcinoma, nasal carcinoma, and metastatic osteosarcoma. The drug is formulated as film-coated tablets in multiple strengths (10 mg, 15 mg, 50 mg) for weight-based dosing.
Why Source from TCS
TCS supplies toceranib phosphate to veterinary pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Toceranib Phosphate 874819-74-6?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Toceranib Phosphate 874819-74-6 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Toceranib Phosphate 874819-74-6?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.